Christensen SB , Hone AJ , Roux I , Kniazeff J , Pin JP , Upert G , Servent D , Glowatzki E , McIntosh JM .

R01 DC006476 NIDCD NIH HHS , R01 GM103801 NIGMS NIH HHS , P01 GM048677 NIGMS NIH HHS , R01 DC012957 NIDCD NIH HHS , R03 DC013374 NIDCD NIH HHS

	Figure 1. (A) Amino acid sequence alignment of the extracellular domains of mouse α9 and α10 subunits. Numbering complies with the numbering of the α9 nAChR subunit presented in the crystal structure of the human α9 extracellular domain (Zouridakis et al., 2014). Arrow heads point at residues thought to interact with α-CT× RgIA4: T61 and D121 (α9) and E197, P200, and D201 (α10), based on comparison with the binding of rat α9 and α10 subunits to α-conotoxin RgIA (Perez et al., 2009; Azam et al., 2015). Conserved residues are highlighted, colors were chosen depending on the chemical properties of the residues. (B) Sequence alignments of the α-conotoxin RgIA–interacting domains of mouse, rat and human α9, and α10 nAChR subunits.
	Figure 2. Functional characterization of mouse α9α10 nAChRs heterologously expressed in Xenopus laevis oocytes. Oocytes expressing mouse α9α10 nAChRs were subjected to two-electrode voltage clamp electrophysiology as described in Materials and Methods. The EC50for activation of α9α10 nAChRs by ACh was 30.1 (23.5–38.7) μM and the Hill slope was 1.1 (0.8–1.4) (n = 5). The EC50 for activation by choline was 601 (311–1160) μM; Hill slope 1.3 (0.5–2.1) maximal efficacy was 50 ± 5% relative to ACh (n = 4). Nicotine failed to evoke currents in all oocytes tested (0.4 ± 0.2%) (n = 4). The values in parenthesis denote the 95% confidence interval.
	Figure 3. RgIA4 selectively blocks mouse α9α10 nAChRs. nAChRs were expressed in Xenopus laevis oocytes. (A) The concentration response curves for α9α10 and α7 are shown. The IC50 for α9α10 was 1.2 (0.95–1.6) nM with a Hill slope of 1.6 (0.91–2.2). The IC50 for α7 was 4.5 (3.1–6.4) μM with a Hill slope of 2.0 (0.84–3.2). The values in parenthesis denote the 95% confidence intervals; n = 3–7 for each condition. (B) Recovery from toxin block of α9α10 is relatively slow. Example trace of block by 33 nM RgIA4. Recovery after 15 min toxin washout was ~2%. Arrows indicate application of 10 μM ACh. (C) At all other indicated nAChR subtypes, RgIA4 (10 μM) blocked less than 50% of the ACh-evoked response; the percent of the ACh-response for each subtype was α1β1δϵ, 95.0 ± 3.8; α1β1δγ, 86.2 ± 3.8; α3β2, 106 ± 2.9; α3β4, 105 ± 0.7; α4β2, 102 ± 3.3; α4β4, 74.3 ± 3.0. n = 3–4 for each condition; ± is S.E.M. Example traces for α4β2, α3β4, and α3β2 are shown. Results are summarized in Table 1.
	Figure 4. RgIA4 prevents oxaliplatin-induced cold allodynia. Mice were injected once per day with oxaliplatin (3.5 mg/kg i.p) or 0.9% saline (vehicle) for control animals. In addition, mice were injected once per day with RgIA4 (40 μg/kg, s.c.) or vehicle. During the treatment period, mice were injected for 2 days, followed by a 2 day break, followed by injection for another 3 days. Twenty-four hours after last injection, mice were assessed for cold allodynia using a cold-plate as described in Materials and Methods. This injection schedule was repeated for two additional weeks. Treatments were stopped on day 21; cold-plate assessment was performed 24 h later on day 22; subsequent testings were performed once a week for three additional weeks. Time to respond to decreasing temperature was measured and indicated on the y axis as the mean ± SEM (n = 8) for each experimental group. Experimenters were blinded to treatment conditions. Data was analyzed using a one-way ANOVA with Dunnett's Multiple Comparison Test, P-values were indicated as: *P < 0.05, **P < 0.01, and ***P < 0.001 for significant difference from vehicle/vehicle control. And 0P < 0.05, 000P < 0.001, and indicating significant difference compared with oxaliplatin/vehicle mice.
	Figure 5. (A) α-Conotoxins do not displace the orthosteric GABABR antagonist CGP54626-Red. GABA, CGP54626, and the indicated α-Ctxs (at 1 μM) were assessed for the ability to displace CGP54626-Red binding from GABABR heterologously expressed in HEK293 cells as described in Material and Methods. Three replicates were obtained for each value and the experiment was repeated three times. (B) α-Conotoxins do not activate GABABR. The indicated α-conotoxins were tested at 1 μM for their ability to activate GABABR heterolgously expressed together with fluorescently tagged G protein subunits in HEK293 cells. At resting state, the G-protein subunits are in close proximity resulting in a strong basal bioluminescence resonance energy transfer (BRET) signal. Activation of GABABR was assessed by monitoring dissociation of Gαi1-Rluc (top) or GαoA-Rluc (bottom) from β2γ2-Venus as measured by the change in BRET. The results after 10 min of toxin incubation are expressed as a percentage of GABA-induced BRET change from basal fluorescence levels. Three replicates were obtained for each value and the experiment was repeated three times.

, , Pubmed

, , Pubmed
Abazeed, Integrative radiogenomic profiling of squamous cell lung cancer. 2013, Pubmed
Adams, Analgesic conotoxins: block and G protein-coupled receptor modulation of N-type (Ca(V) 2.2) calcium channels. 2012, Pubmed
Adams, Mechanisms of conotoxin inhibition of N-type (Ca(v)2.2) calcium channels. 2013, Pubmed
Austin, Regulatory T cells attenuate neuropathic pain following peripheral nerve injury and experimental autoimmune neuritis. 2012, Pubmed
Avan, Platinum-induced neurotoxicity and preventive strategies: past, present, and future. 2015, Pubmed
Azam, Amino acid residues that confer high selectivity of the alpha6 nicotinic acetylcholine receptor subunit to alpha-conotoxin MII[S4A,E11A,L15A]. 2008, Pubmed , Xenbase
Azam, Molecular basis for the differential sensitivity of rat and human α9α10 nAChRs to α-conotoxin RgIA. 2012, Pubmed , Xenbase
Azam, Molecular interaction of α-conotoxin RgIA with the rat α9α10 nicotinic acetylcholine receptor. 2015, Pubmed
Azam, Alpha-conotoxins as pharmacological probes of nicotinic acetylcholine receptors. 2009, Pubmed
Backhaus, Surfactant inhibits ATP-induced release of interleukin-1β via nicotinic acetylcholine receptors. 2017, Pubmed
Banach, Chemotherapy-induced neuropathies-a growing problem for patients and health care providers. 2017, Pubmed
Berecki, Differential Cav2.1 and Cav2.3 channel inhibition by baclofen and α-conotoxin Vc1.1 via GABAB receptor activation. 2014, Pubmed
Boffi, Differential Contribution of Subunit Interfaces to α9α10 Nicotinic Acetylcholine Receptor Function. 2017, Pubmed
Brady, Prescription Opioid Misuse, Abuse, and Treatment in the United States: An Update. 2016, Pubmed
Callaghan, Analgesic alpha-conotoxins Vc1.1 and Rg1A inhibit N-type calcium channels in rat sensory neurons via GABAB receptor activation. 2008, Pubmed , Xenbase
Callaghan, Analgesic α-conotoxins Vc1.1 and RgIA inhibit N-type calcium channels in sensory neurons of α9 nicotinic receptor knockout mice. 2010, Pubmed
Carstens, Engineering of conotoxins for the treatment of pain. 2011, Pubmed
Cartier, A new alpha-conotoxin which targets alpha3beta2 nicotinic acetylcholine receptors. 1996, Pubmed , Xenbase
Castro, α-Conotoxin Vc1.1 inhibits human dorsal root ganglion neuroexcitability and mouse colonic nociception via GABAB receptors. 2017, Pubmed
Clark, The engineering of an orally active conotoxin for the treatment of neuropathic pain. 2010, Pubmed
Colloca, Neuropathic pain. 2017, Pubmed
Comps-Agrar, The oligomeric state sets GABA(B) receptor signalling efficacy. 2011, Pubmed
Costigan, Neuropathic pain: a maladaptive response of the nervous system to damage. 2009, Pubmed
Cuny, γ-Aminobutyric acid type B (GABAB) receptor expression is needed for inhibition of N-type (Cav2.2) calcium channels by analgesic α-conotoxins. 2012, Pubmed
Del Bufalo, Alpha9 alpha10 nicotinic acetylcholine receptors as target for the treatment of chronic pain. 2014, Pubmed
Di Cesare Mannelli, α-conotoxin RgIA protects against the development of nerve injury-induced chronic pain and prevents both neuronal and glial derangement. 2014, Pubmed
Dutertre, Nicotinic acetylcholine receptor inhibitors derived from snake and snail venoms. 2017, Pubmed
Elgoyhen, alpha10: a determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells. 2001, Pubmed , Xenbase
Elgoyhen, Alpha 9: an acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. 1994, Pubmed , Xenbase
Filchakova, Functional expression of human α9* nicotinic acetylcholine receptors in X. laevis oocytes is dependent on the α9 subunit 5' UTR. 2013, Pubmed , Xenbase
Galés, Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes. 2006, Pubmed
Grace, Pathological pain and the neuroimmune interface. 2014, Pubmed
Hanin, Competing targets of microRNA-608 affect anxiety and hypertension. 2014, Pubmed
Hao, Attenuation of CNS inflammatory responses by nicotine involves α7 and non-α7 nicotinic receptors. 2011, Pubmed
Hecker, Phosphocholine-Modified Macromolecules and Canonical Nicotinic Agonists Inhibit ATP-Induced IL-1β Release. 2015, Pubmed
Hershman, Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. 2014, Pubmed
Holtman, The novel small molecule α9α10 nicotinic acetylcholine receptor antagonist ZZ-204G is analgesic. 2011, Pubmed , Xenbase
Hone, α9-containing nicotinic acetylcholine receptors and the modulation of pain. 2018, Pubmed
Huynh, Novel mechanism of voltage-gated N-type (Cav2.2) calcium channel inhibition revealed through α-conotoxin Vc1.1 activation of the GABA(B) receptor. 2015, Pubmed
Ji, Pain regulation by non-neuronal cells and inflammation. 2016, Pubmed
Johnson, alpha-Conotoxin ImI exhibits subtype-specific nicotinic acetylcholine receptor blockade: preferential inhibition of homomeric alpha 7 and alpha 9 receptors. 1995, Pubmed , Xenbase
Kaas, ConoServer: updated content, knowledge, and discovery tools in the conopeptide database. 2012, Pubmed
Kilkenny, Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. 2010, Pubmed
Klimis, A novel mechanism of inhibition of high-voltage activated calcium channels by α-conotoxins contributes to relief of nerve injury-induced neuropathic pain. 2011, Pubmed
Lebbe, Conotoxins targeting nicotinic acetylcholine receptors: an overview. 2014, Pubmed
Lees, Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. 2017, Pubmed
Li, Anti-hypersensitive effect of intramuscular administration of αO-conotoxin GeXIVA[1,2] and GeXIVA[1,4] in rats of neuropathic pain. 2016, Pubmed
Loram, Enduring reversal of neuropathic pain by a single intrathecal injection of adenosine 2A receptor agonists: a novel therapy for neuropathic pain. 2009, Pubmed
Loram, Intrathecal injection of adenosine 2A receptor agonists reversed neuropathic allodynia through protein kinase (PK)A/PKC signaling. 2013, Pubmed
Luo, Cloning, synthesis, and characterization of αO-conotoxin GeXIVA, a potent α9α10 nicotinic acetylcholine receptor antagonist. 2015, Pubmed , Xenbase
Luo, alpha-conotoxin AuIB selectively blocks alpha3 beta4 nicotinic acetylcholine receptors and nicotine-evoked norepinephrine release. 1998, Pubmed , Xenbase
McClure-Begley, Presynaptic GABAB autoreceptor regulation of nicotinic acetylcholine receptor mediated [(3)H]-GABA release from mouse synaptosomes. 2014, Pubmed
McIntosh, Alpha9 nicotinic acetylcholine receptors and the treatment of pain. 2009, Pubmed , Xenbase
Mohammadi, Conotoxin Interactions with α9α10-nAChRs: Is the α9α10-Nicotinic Acetylcholine Receptor an Important Therapeutic Target for Pain Management? 2015, Pubmed
Mohammadi, α9-nicotinic acetylcholine receptors contribute to the maintenance of chronic mechanical hyperalgesia, but not thermal or mechanical allodynia. 2014, Pubmed
Napier, Intrathecal α-conotoxins Vc1.1, AuIB and MII acting on distinct nicotinic receptor subtypes reverse signs of neuropathic pain. 2012, Pubmed
Nevin, Are alpha9alpha10 nicotinic acetylcholine receptors a pain target for alpha-conotoxins? 2007, Pubmed , Xenbase
Pacini, The α9α10 nicotinic receptor antagonist α-conotoxin RgIA prevents neuropathic pain induced by oxaliplatin treatment. 2016, Pubmed
Peng, Microglia and monocytes synergistically promote the transition from acute to chronic pain after nerve injury. 2016, Pubmed
Pérez, Molecular modeling of the alpha9alpha10 nicotinic acetylcholine receptor subtype. 2009, Pubmed
Radcliffe, Nicotinic modulation of glutamate and GABA synaptic transmission of hippocampal neurons. 1999, Pubmed
Richter, Phosphocholine - an agonist of metabotropic but not of ionotropic functions of α9-containing nicotinic acetylcholine receptors. 2016, Pubmed , Xenbase
Romero, Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain. 2017, Pubmed
Roux, Assessment of the expression and role of the α1-nAChR subunit in efferent cholinergic function during the development of the mammalian cochlea. 2016, Pubmed
Sadeghi, Analgesic conopeptides targeting G protein-coupled receptors reduce excitability of sensory neurons. 2017, Pubmed
Satkunanathan, Alpha-conotoxin Vc1.1 alleviates neuropathic pain and accelerates functional recovery of injured neurones. 2005, Pubmed
Sgard, A novel human nicotinic receptor subunit, alpha10, that confers functionality to the alpha9-subunit. 2002, Pubmed , Xenbase
Sievers, Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. 2011, Pubmed
Umana, Neuronal nicotinic receptors as analgesic targets: it's a winding road. 2013, Pubmed
van Hecke, Neuropathic pain in the general population: a systematic review of epidemiological studies. 2014, Pubmed
van Lierop, Dicarba α-conotoxin Vc1.1 analogues with differential selectivity for nicotinic acetylcholine and GABAB receptors. 2013, Pubmed , Xenbase
Verbitsky, Mixed nicotinic-muscarinic properties of the alpha9 nicotinic cholinergic receptor. 2000, Pubmed , Xenbase
Vincler, Molecular mechanism for analgesia involving specific antagonism of alpha9alpha10 nicotinic acetylcholine receptors. 2006, Pubmed
Vincler, Targeting the alpha9alpha10 nicotinic acetylcholine receptor to treat severe pain. 2007, Pubmed
Wala, Novel small molecule α9α10 nicotinic receptor antagonist prevents and reverses chemotherapy-evoked neuropathic pain in rats. 2012, Pubmed
Whiteaker, Discovery, synthesis, and structure activity of a highly selective alpha7 nicotinic acetylcholine receptor antagonist. 2007, Pubmed , Xenbase
Wright, Limited efficacy of α-conopeptides, Vc1.1 and RgIA, to inhibit sensory neuron CaV current. 2015, Pubmed
Xiao, Chronic nicotine selectively enhances alpha4beta2* nicotinic acetylcholine receptors in the nigrostriatal dopamine pathway. 2009, Pubmed
Zheng, Discovery of non-peptide, small molecule antagonists of α9α10 nicotinic acetylcholine receptors as novel analgesics for the treatment of neuropathic and tonic inflammatory pain. 2011, Pubmed
Zouridakis, Crystal structures of free and antagonist-bound states of human α9 nicotinic receptor extracellular domain. 2014, Pubmed , Xenbase
Zwier, A fluorescent ligand-binding alternative using Tag-lite® technology. 2010, Pubmed